ST91

ST91 is a α2-adrenoceptor (α2AR) agonist. ST91 activates both α2AAR and non-α2AAR subtypes to produce spinal antinociception[1][2][3].

Product Specifications

CAS Number

[4749-61-5]

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/st91.html

Purity

99.75

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CCC1=C(NC2=NCCN2)C(CC)=CC=C1.[H]Cl

Molecular Formula

C13H20ClN3

Molecular Weight

253.77

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Graham BA, et, al. Synergistic interactions between two alpha (2) -adrenoceptor agonists, dexmedetomidine and ST-91, in two substrains of Sprague-Dawley rats. Pain. 2000 Mar;85 (1-2) :135-43. |[2]Maccari S, et, al. α-Adrenoceptor stimulation attenuates melanoma growth in mice. Br J Pharmacol. 2022 Apr;179 (7) :1371-1383. |[3]Stone LS, et, al. ST91 [2- (2,6-diethylphenylamino) -2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional alpha-2A- or alpha-2C-adrenergic receptors. J Pharmacol Exp Ther. 2007 Dec;323 (3) :899-906.